These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 29278442

  • 1. Sevelamer hydrochloride suppresses proliferation of parathyroid cells during the early phase of chronic renal failure in rats.
    Xiao X, Liu Y, Zhong X, Liu Y, Zhou D, Xiong X, Ran J.
    Nephrology (Carlton); 2019 Jan; 24(1):127-133. PubMed ID: 29278442
    [Abstract] [Full Text] [Related]

  • 2. Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.
    Nagano N, Miyata S, Obana S, Ozai M, Kobayashi N, Fukushima N, Burke SK, Wada M.
    Nephrol Dial Transplant; 2001 Sep; 16(9):1870-8. PubMed ID: 11522872
    [Abstract] [Full Text] [Related]

  • 3. Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats.
    Nagano N, Miyata S, Obana S, Kobayashi N, Abe M, Fukushima N, Wada M.
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii81-5. PubMed ID: 12771309
    [Abstract] [Full Text] [Related]

  • 4. Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency.
    Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M.
    Nephrol Dial Transplant; 2006 Mar; 21(3):634-43. PubMed ID: 16169864
    [Abstract] [Full Text] [Related]

  • 5. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
    Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E.
    J Am Soc Nephrol; 2002 Sep; 13(9):2299-308. PubMed ID: 12191974
    [Abstract] [Full Text] [Related]

  • 6. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.
    Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E.
    Kidney Int; 2003 Nov; 64(5):1653-61. PubMed ID: 14531797
    [Abstract] [Full Text] [Related]

  • 7. [Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].
    Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M.
    Clin Calcium; 2005 Sep; 15 Suppl 1():35-9; discussion 39-40. PubMed ID: 16272627
    [Abstract] [Full Text] [Related]

  • 8. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.
    Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK, Wada M.
    Nephrol Dial Transplant; 2003 Oct; 18(10):2014-23. PubMed ID: 13679475
    [Abstract] [Full Text] [Related]

  • 9. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.
    Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M.
    Kidney Int; 2006 Feb; 69(3):531-7. PubMed ID: 16395276
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Radioimmunoassay of carboxyl and amino terminal fragments of parathyroid hormone for the evaluation of secondary hyperparathyroidism in chronic renal failure.
    Zanella MT, Silva MC, Peres RB, Ferreira SR, Draibe SA, Vieira JG.
    Braz J Med Biol Res; 1990 Feb; 23(3-4):235-43. PubMed ID: 2094538
    [Abstract] [Full Text] [Related]

  • 16. NF-κB activation contributes to parathyroid cell proliferation in chronic kidney disease.
    Kan S, Zhang W, Mao J, Wang M, Ni L, Zhang M, Zhang Q, Chen J.
    J Nephrol; 2018 Dec; 31(6):941-951. PubMed ID: 30171599
    [Abstract] [Full Text] [Related]

  • 17. Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.
    Terai K, Nara H, Takakura K, Mizukami K, Sanagi M, Fukushima S, Fujimori A, Itoh H, Okada M.
    Br J Pharmacol; 2009 Apr; 156(8):1267-78. PubMed ID: 19302594
    [Abstract] [Full Text] [Related]

  • 18. Effects of FGF-23-mediated ERK/MAPK signaling pathway on parathyroid hormone secretion of parathyroid cells in rats with secondary hyperparathyroidism.
    Chen XJ, Chen X, Wu WJ, Zhou Q, Gong XH, Shi BM.
    J Cell Physiol; 2018 Sep; 233(9):7092-7102. PubMed ID: 29633272
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis.
    Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T, Akiba T, Nitta K.
    Nephron Clin Pract; 2008 Sep; 108(4):c278-83. PubMed ID: 18434749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.